RGEN Repligen Corporation - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
RGEN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Instruments & Supplies
Current Price
Live
$162.02
Analyst Target
$190.89
+17.8%
Upside
52W High
$182.52
52W Low
$102.97
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
RGEN's Advanced Deterministic Scorecard reveals a weak fundamental health with a Piotroski F-Score of 4/9, indicating borderline stability. Despite strong revenue growth and solid gross margins, the company suffers from extremely low profitability metrics, including a near-zero profit margin (0.25%) and ROE (0.08%), which severely undermine its financial strength. Valuation multiples are exceptionally high, with a P/E of 8101 and a Price/Sales of 12.88, suggesting the stock trades at a significant premium, likely due to growth expectations. While analysts maintain a 'buy' recommendation and recent insider selling is concerning, the technical trend is bearish, and long-term price performance remains negative despite a recent 6-month rebound.
Key Strengths
Strong revenue growth (21.9% YoY), outpacing sector average of 9.8%
High gross margin (51.59%), indicating pricing power or cost efficiency in core operations
Exceptionally strong liquidity position with current ratio of 8.36 and quick ratio of 6.85
Low debt/equity ratio (0.33), below sector average of 0.92, suggesting conservative capital structure
Analyst consensus remains positive with a 'buy' rating and target price of $190.89 implying 17.8% upside
Key Risks
Critically low Piotroski F-Score (4/9) signals weak financial health and poor earnings quality
Extremely high P/E ratio (8101) indicates potential overvaluation or earnings collapse risk
Near-zero profitability: profit margin (0.25%) and ROE (0.08%) are alarmingly low for a company of this size
Insider selling activity: $12.1M in sales over last 6 months with no buys, signaling bearish sentiment from insiders
Long-term price underperformance: 5-year return of -27.1% despite recent short-term rebound
AI Fair Value Estimate
Based on comprehensive analysis
$4.08
-97.5% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare RGEN against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning RGEN from our newsroom.
Newest → oldest
No matching news yet.